First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

Abstract Background VT1021 is a cyclic peptide that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). TSP-1 reprograms the TME via binding to CD36 and CD47 to induce tumor and endothelial cell apoptosis as we...

Full description

Bibliographic Details
Main Authors: Devalingam Mahalingam, Wael Harb, Amita Patnaik, Andrea Bullock, Randolph S. Watnick, Melanie Y. Vincent, Jian Jenny Chen, Suming Wang, Harold Pestana, Judy Chao, James Mahoney, Michael Cieslewicz, Jing Watnick
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-024-00433-x

Internet

https://doi.org/10.1038/s43856-024-00433-x

Similar Items